Emmaus Life Sciences Inc
OTC:EMMA
Net Margin
Emmaus Life Sciences Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Emmaus Life Sciences Inc
OTC:EMMA
|
989.9k USD |
-27%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
646.4B USD |
26%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
420.3B USD |
25%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
198.5B CHF |
14%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
179.7B GBP |
15%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
190.2B CHF |
25%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
36%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
208.3B USD |
26%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.6B USD |
17%
|
Emmaus Life Sciences Inc
Glance View
Emmaus Life Sciences, Inc. operates as a biopharmaceutical company. The company is headquartered in Torrance, California and currently employs 58 full-time employees. The company went IPO on 2000-05-09. The Company’s lead product, Endari was approved by the United States Food and Drug Administration (FDA) to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission. Endari’s safety profile was like the placebo and Endari was well-tolerated in pediatric and adult patients alike. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003 and ELS002. The Company’s subsidiaries include EMI Holding, Inc., Emmaus Medical, Inc., Emmaus Medical Japan, Inc., Newfield Nutrition Corporation, Emmaus Medical Europe Limited, Emmaus Medical Europe Limited and Emmaus Life Sciences, Co. Ltd.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Emmaus Life Sciences Inc's most recent financial statements, the company has Net Margin of -26.8%.
You don't have any saved screeners yet